SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022

EW Kagucia, AK Ziraba, J Nyagwange, B Kutima, M Kimani, D Akech, M Ng’oda, A Sigilai, D Mugo, H Karanja, J Gitonga, A Karani, M Toroitich, B Karia, M Otiende, A Njeri, R Aman, P Amoth, M Mwangangi, K Kasera, W Ng’ang’a, S Voller, LI Ochola-Oyier, C Bottomley, A Nyaguara, PK Munywoki, G Bigogo, E Maitha, S Uyoga, KE Gallagher, AO Etyang, E Barasa, J Mwangangi, P Bejon, IMO Adetifa, GM Warimwe, JAG Scott, A Agweyu
doi: https://doi.org/10.1101/2022.10.10.22280824

Article Information

doi 
https://doi.org/10.1101/2022.10.10.22280824
History 
  • October 24, 2022.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. EW Kagucia1,*,#,
  2. AK Ziraba2,*,
  3. J Nyagwange1,
  4. B Kutima1,
  5. M Kimani1,
  6. D Akech1,
  7. M Ng’oda2,
  8. A Sigilai1,
  9. D Mugo1,
  10. H Karanja1,
  11. J Gitonga1,
  12. A Karani1,
  13. M Toroitich1,
  14. B Karia1,
  15. M Otiende1,
  16. A Njeri2,
  17. R Aman3,
  18. P Amoth3,
  19. M Mwangangi3,
  20. K Kasera3,
  21. W Ng’ang’a4,
  22. S Voller1,5,
  23. LI Ochola-Oyier1,
  24. C Bottomley5,
  25. A Nyaguara1,
  26. PK Munywoki6,
  27. G Bigogo7,
  28. E Maitha8,
  29. S Uyoga1,
  30. KE Gallagher1,
  31. AO Etyang1,
  32. E Barasa1,
  33. J Mwangangi,
  34. P Bejon1,9,
  35. IMO Adetifa1,5,
  36. GM Warimwe1,9,*,
  37. JAG Scott1,5,* and
  38. A Agweyu1,*
  1. 1KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
  2. 2African Population and Health Research Center
  3. 3Ministry of Health, Kenya
  4. 4Presidential Policy and Strategy Unit, The Presidency, Government of Kenya
  5. 5London School of Hygiene and Tropical Medicine, UK
  6. 6US Centers of Disease Control and Prevention, Center for Global Health, Division for Global Health Protection, Nairobi, Kenya
  7. 7KEMRI Centre for Global Health Research, Kisumu, Kenya
  8. 8Department of Health, Kilifi County, Kenya
  9. 9Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford University, UK
  1. ↵#Contact information
    Corresponding author: E. Wangeci Kagucia, PhD, KEMRI-Wellcome Trust Research Programme, Department of Epidemiology and Demography, P. O. Box 230-80108, Kilifi, Kenya, ekagucia{at}kemri-wellcome.org

  1. ↵* These authors contributed equally to this work

Back to top
Posted October 24, 2022.
Download PDF

Supplementary Material

Data/Code
Email
SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022
EW Kagucia, AK Ziraba, J Nyagwange, B Kutima, M Kimani, D Akech, M Ng’oda, A Sigilai, D Mugo, H Karanja, J Gitonga, A Karani, M Toroitich, B Karia, M Otiende, A Njeri, R Aman, P Amoth, M Mwangangi, K Kasera, W Ng’ang’a, S Voller, LI Ochola-Oyier, C Bottomley, A Nyaguara, PK Munywoki, G Bigogo, E Maitha, S Uyoga, KE Gallagher, AO Etyang, E Barasa, J Mwangangi, P Bejon, IMO Adetifa, GM Warimwe, JAG Scott, A Agweyu
medRxiv 2022.10.10.22280824; doi: https://doi.org/10.1101/2022.10.10.22280824
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area